Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 464

1.

Mycobacterial immunotherapy for prostate cancer: where can we go from here?

Stavrinides V, Dalgleish A, Copier JP, Moore CM.

Nat Rev Urol. 2020 Jan 29. doi: 10.1038/s41585-020-0283-2. [Epub ahead of print] No abstract available.

PMID:
31996816
2.

Evaluation of functional outcomes after a second focal high-intensity focused ultrasonography (HIFU) procedure in men with primary localized, non-metastatic prostate cancer: results from the HIFU Evaluation and Assessment of Treatment (HEAT) registry.

Lovegrove CE, Peters M, Guillaumier S, Arya M, Afzal N, Dudderidge T, Hosking-Jervis F, Hindley RJ, Lewi H, McCartan N, Moore CM, Nigam R, Ogden C, Persad R, Virdi J, Winkler M, Emberton M, Ahmed HU, Shah TT, Minhas S.

BJU Int. 2020 Jan 23. doi: 10.1111/bju.15004. [Epub ahead of print]

PMID:
31971335
3.

"TREXIT 2020": why the time to abandon transrectal prostate biopsy starts now.

Grummet J, Gorin MA, Popert R, O'Brien T, Lamb AD, Hadaschik B, Radtke JP, Wagenlehner F, Baco E, Moore CM, Emberton M, George AK, Davis JW, Szabo RJ, Buckley R, Loblaw A, Allaway M, Kastner C, Briers E, Royce PL, Frydenberg M, Murphy DG, Woo HH.

Prostate Cancer Prostatic Dis. 2020 Mar;23(1):62-65. doi: 10.1038/s41391-020-0204-8. Epub 2020 Jan 13. Review. No abstract available.

PMID:
31932659
4.

Prostate Specific Antigen Criteria to Diagnose Failure of Cancer Control following Focal Therapy of Nonmetastatic Prostate Cancer Using High Intensity Focused Ultrasound.

Huber PM, Afzal N, Arya M, Boxler S, Dudderidge T, Emberton M, Guillaumier S, Hindley RG, Hosking-Jervis F, Leemann L, Lewi H, McCartan N, Moore CM, Nigam R, Odgen C, Persad R, Thalmann GN, Virdi J, Winkler M, Ahmed HU.

J Urol. 2020 Jan 13:101097JU0000000000000747. doi: 10.1097/JU.0000000000000747. [Epub ahead of print]

PMID:
31928408
5.

Endogenous cueing effects for detection can be accounted for by a decision model of selective attention.

Johnson ML, Palmer J, Moore CM, Boynton GM.

Psychon Bull Rev. 2020 Jan 6. doi: 10.3758/s13423-019-01698-3. [Epub ahead of print]

PMID:
31907851
6.

DWI and PRECISE criteria in men on active surveillance for prostate cancer: A multicentre preliminary experience of different ADC calculations.

Giganti F, Pecoraro M, Fierro D, Campa R, Del Giudice F, Punwani S, Kirkham A, Allen C, Emberton M, Catalano C, Moore CM, Panebianco V.

Magn Reson Imaging. 2020 Apr;67:50-58. doi: 10.1016/j.mri.2019.12.007. Epub 2019 Dec 30.

PMID:
31899283
7.

Architecture of the chromatin remodeler RSC and insights into its nucleosome engagement.

Patel AB, Moore CM, Greber BJ, Luo J, Zukin SA, Ranish J, Nogales E.

Elife. 2019 Dec 30;8. pii: e54449. doi: 10.7554/eLife.54449.

8.

Interobserver reproducibility of the PRECISE scoring system for prostate MRI on active surveillance: results from a two-centre pilot study.

Giganti F, Pecoraro M, Stavrinides V, Stabile A, Cipollari S, Sciarra A, Kirkham A, Allen C, Punwani S, Emberton M, Catalano C, Moore CM, Panebianco V.

Eur Radiol. 2019 Dec 16. doi: 10.1007/s00330-019-06557-2. [Epub ahead of print]

PMID:
31844959
9.

Magnetic Resonance Imaging Should Be Used in the Active Surveillance of Patients with Localised Prostate Cancer.

Kasivisvanathan V, Giganti F, Emberton M, Moore CM.

Eur Urol. 2020 Mar;77(3):318-319. doi: 10.1016/j.eururo.2019.11.014. Epub 2019 Nov 25. No abstract available.

PMID:
31780103
10.

An efficient and novel technology for the extraction of parasite genomic DNA from whole blood or culture.

Clark DJ, Moore CM, Flanagan M, Bocxlaer KV, Piperaki ET, Yardley V, Croft SL, Tyson J, Whitehouse SP, O'Halloran J, Krishna S, Staines HM.

Biotechniques. 2020 Feb;68(2):79-84. doi: 10.2144/btn-2019-0086. Epub 2019 Nov 27.

11.

The role of object history in establishing object correspondence.

Stepper MY, Moore CM, Rolke B, Hein E.

Atten Percept Psychophys. 2019 Nov 26. doi: 10.3758/s13414-019-01923-0. [Epub ahead of print]

PMID:
31773506
12.

Added value of diffusion-weighted images and dynamic contrast enhancement in multiparametric magnetic resonance imaging for the detection of clinically significant prostate cancer in the PICTURE trial.

Eldred-Evans D, Neves JB, Simmons LAM, Kanthabalan A, McCartan N, Shah TT, Arya M, Charman SC, Freeman A, Moore CM, Punwani S, Emberton M, Ahmed HU.

BJU Int. 2020 Mar;125(3):391-398. doi: 10.1111/bju.14953. Epub 2019 Dec 11.

PMID:
31733173
13.

Automatic segmentation of prostate MRI using convolutional neural networks: Investigating the impact of network architecture on the accuracy of volume measurement and MRI-ultrasound registration.

Ghavami N, Hu Y, Gibson E, Bonmati E, Emberton M, Moore CM, Barratt DC.

Med Image Anal. 2019 Dec;58:101558. doi: 10.1016/j.media.2019.101558. Epub 2019 Sep 11.

14.

Platelet transfusion thresholds in neonatal medicine.

Moore CM, Curley A.

Early Hum Dev. 2019 Nov;138:104845. doi: 10.1016/j.earlhumdev.2019.104845. Epub 2019 Sep 2.

PMID:
31488313
15.

Prediction of significant prostate cancer in biopsy-naïve men: Validation of a novel risk model combining MRI and clinical parameters and comparison to an ERSPC risk calculator and PI-RADS.

Radtke JP, Giganti F, Wiesenfarth M, Stabile A, Marenco J, Orczyk C, Kasivisvanathan V, Nyarangi-Dix JN, Schütz V, Dieffenbacher S, Görtz M, Stenzinger A, Roth W, Freeman A, Punwani S, Bonekamp D, Schlemmer HP, Hohenfellner M, Emberton M, Moore CM.

PLoS One. 2019 Aug 26;14(8):e0221350. doi: 10.1371/journal.pone.0221350. eCollection 2019.

16.

MRI in early detection of prostate cancer.

Giganti F, Moore CM.

Curr Opin Urol. 2019 Nov;29(6):563-568. doi: 10.1097/MOU.0000000000000668.

PMID:
31436569
18.

Multiparametric MRI for prostate cancer diagnosis: current status and future directions.

Stabile A, Giganti F, Rosenkrantz AB, Taneja SS, Villeirs G, Gill IS, Allen C, Emberton M, Moore CM, Kasivisvanathan V.

Nat Rev Urol. 2020 Jan;17(1):41-61. doi: 10.1038/s41585-019-0212-4. Epub 2019 Jul 17. Review.

PMID:
31316185
19.

Object correspondence: Using perceived causality to infer how the visual system knows what went where.

Moore CM, Stephens T, Hein E.

Atten Percept Psychophys. 2020 Jan;82(1):181-192. doi: 10.3758/s13414-019-01763-y.

PMID:
31214971
20.

Consistent Biopsy Quality and Gleason Grading Within the Global Active Surveillance Global Action Plan 3 Initiative: A Prerequisite for Future Studies.

van der Kwast TH, Helleman J, Nieboer D, Bruinsma SM, Roobol MJ; Movember Foundation's Global Action Plan Prostate Cancer Active Surveillance (GAP3) Consortium, Trock B, Ehdaie B, Carroll P, Filson C, Kim J, Logothetis C, Morgan T, Klotz L, Pickles T, Hyndman E, Moore CM, Gnanapragasam V, Van Hemelrijck M, Dasgupta P, Bangma C, Roobol M, Villers A, Rannikko A, Valdagni R, Perry A, Hugosson J, Rubio-Briones J, Bjartell A, Hefermehl L, Shiong LL, Frydenberg M, Kakehi Y, Chung BH, van der Kwast T, Obbink H, van der Linden W, Hulsen T, de Jonge C, Kattan M, Xinge J, Muir K, Lophatananon A, Fahey M, Steyerberg E, Nieboer D, Zhang L, Guo W, Benfante N, Cowan J, Patil D, Tolosa E, Kim TK, Mamedov A, LaPointe V, Crump T, Kimberly-Duffell J, Santaolalla A, Nieboer D, Olivier JT, Rancati T, Ahlgren H, Mascarós J, Löfgren A, Lehmann K, Lin CH, Hirama H, Lee KS, Jenster G, Auvinen A, Bjartell A, Haider M, van Bochove K, Carter B, Gledhill S, Buzza M, Bangma C, Roobol M, Bruinsma S, Helleman J.

Eur Urol Oncol. 2019 May;2(3):333-336. doi: 10.1016/j.euo.2018.08.017. Epub 2018 Sep 13.

PMID:
31200849
21.

Magnetic Resonance Imaging-targeted Biopsy Versus Systematic Biopsy in the Detection of Prostate Cancer: A Systematic Review and Meta-analysis.

Kasivisvanathan V, Stabile A, Neves JB, Giganti F, Valerio M, Shanmugabavan Y, Clement KD, Sarkar D, Philippou Y, Thurtle D, Deeks J, Emberton M, Takwoingi Y, Moore CM.

Eur Urol. 2019 Sep;76(3):284-303. doi: 10.1016/j.eururo.2019.04.043. Epub 2019 May 24. Review.

PMID:
31130434
22.

The Evolution of MRI of the Prostate: The Past, the Present, and the Future.

Giganti F, Rosenkrantz AB, Villeirs G, Panebianco V, Stabile A, Emberton M, Moore CM.

AJR Am J Roentgenol. 2019 Aug;213(2):384-396. doi: 10.2214/AJR.18.20796. Epub 2019 Apr 30. Review.

PMID:
31039022
23.

VERDICT MRI for Prostate Cancer: Intracellular Volume Fraction versus Apparent Diffusion Coefficient.

Johnston EW, Bonet-Carne E, Ferizi U, Yvernault B, Pye H, Patel D, Clemente J, Piga W, Heavey S, Sidhu HS, Giganti F, O'Callaghan J, Brizmohun Appayya M, Grey A, Saborowska A, Ourselin S, Hawkes D, Moore CM, Emberton M, Ahmed HU, Whitaker H, Rodriguez-Justo M, Freeman A, Atkinson D, Alexander D, Panagiotaki E, Punwani S.

Radiology. 2019 May;291(2):391-397. doi: 10.1148/radiol.2019181749. Epub 2019 Apr 2.

24.

Development of Technologic Solutions to Address Complex Local Requirements of an International Prostate Cancer Clinical Quality Registry.

Sampurno F, Kannan A, Lucas M, Liman J, Connor SE, Pearman E, Millar JL, Moore CM, Villanti P, James E, Huland H, Litwin MS, Evans SM.

JCO Clin Cancer Inform. 2019 Mar;3:1-11. doi: 10.1200/CCI.18.00114.

25.

Standardized Magnetic Resonance Imaging Reporting Using the Prostate Cancer Radiological Estimation of Change in Sequential Evaluation Criteria and Magnetic Resonance Imaging/Transrectal Ultrasound Fusion with Transperineal Saturation Biopsy to Select Men on Active Surveillance.

Dieffenbacher S, Nyarangi-Dix J, Giganti F, Bonekamp D, Kesch C, Müller-Wolf MB, Schütz V, Gasch C, Hatiboglu G, Hauffe M, Stenzinger A, Duensing S, Schlemmer HP, Moore CM, Hohenfellner M, Radtke JP.

Eur Urol Focus. 2019 Mar 13. pii: S2405-4569(19)30076-8. doi: 10.1016/j.euf.2019.03.001. [Epub ahead of print]

PMID:
30878348
26.

Magnetic resonance imaging and prostate cancer: Perspectives from the UK, Europe and USA.

Giganti F, Stabile A, Moore CM.

Arch Esp Urol. 2019 Mar;72(2):135-141.

PMID:
30855014
27.

Prostate cancer treated with irreversible electroporation: MRI-based volumetric analysis and oncological outcome.

Giganti F, Stabile A, Giona S, Marenco J, Orczyk C, Moore CM, Allen C, Kirkham A, Emberton M, Punwani S.

Magn Reson Imaging. 2019 May;58:143-147. doi: 10.1016/j.mri.2019.02.003. Epub 2019 Feb 12.

PMID:
30768957
28.

Medium-term oncological outcomes in a large cohort of men treated with either focal or hemi-ablation using high-intensity focused ultrasonography for primary localized prostate cancer.

Stabile A, Orczyk C, Hosking-Jervis F, Giganti F, Arya M, Hindley RG, Dickinson L, Allen C, Punwani S, Jameson C, Freeman A, McCartan N, Montorsi F, Briganti A, Ahmed HU, Emberton M, Moore CM.

BJU Int. 2019 Sep;124(3):431-440. doi: 10.1111/bju.14710. Epub 2019 Mar 18.

PMID:
30753756
29.

Best practice in active surveillance for men with prostate cancer: a Prostate Cancer UK consensus statement.

Merriel SWD, Hetherington L, Seggie A, Castle JT, Cross W, Roobol MJ, Gnanapragasam V, Moore CM; Prostate Cancer UK Expert Reference Group on Active Surveillance.

BJU Int. 2019 Jul;124(1):47-54. doi: 10.1111/bju.14707. Epub 2019 Mar 7.

30.

Pathological Findings and Magnetic Resonance Imaging Concordance at Salvage Radical Prostatectomy for Local Recurrence following Partial Ablation Using High Intensity Focused Ultrasound.

Thompson JE, Sridhar AN, Tan WS, Freeman A, Haider A, Allen C, Moore CM, Orczyk C, Mazzon G, Khetrapal P, Shaw G, Rajan P, Mohammed A, Briggs TP, Nathan S, Kelly JD, Sooriakumaran P.

J Urol. 2019 Jun;201(6):1134-1143. doi: 10.1097/JU.0000000000000135.

PMID:
30730409
31.

Daytime temperature is sensed by phytochrome B in Arabidopsis through a transcriptional activator HEMERA.

Qiu Y, Li M, Kim RJ, Moore CM, Chen M.

Nat Commun. 2019 Jan 11;10(1):140. doi: 10.1038/s41467-018-08059-z.

32.

The SmartTarget Biopsy Trial: A Prospective, Within-person Randomised, Blinded Trial Comparing the Accuracy of Visual-registration and Magnetic Resonance Imaging/Ultrasound Image-fusion Targeted Biopsies for Prostate Cancer Risk Stratification.

Hamid S, Donaldson IA, Hu Y, Rodell R, Villarini B, Bonmati E, Tranter P, Punwani S, Sidhu HS, Willis S, van der Meulen J, Hawkes D, McCartan N, Potyka I, Williams NR, Brew-Graves C, Freeman A, Moore CM, Barratt D, Emberton M, Ahmed HU.

Eur Urol. 2019 May;75(5):733-740. doi: 10.1016/j.eururo.2018.08.007. Epub 2018 Dec 6.

33.

Observing different model types interspersed with physical practice has no effect on consolidation or motor learning of an elbow flexion-extension task.

Moore CM, Lelievre N, Ste-Marie DM.

Hum Mov Sci. 2019 Feb;63:96-107. doi: 10.1016/j.humov.2018.11.014. Epub 2018 Nov 30.

PMID:
30508690
34.

A picture is worth a thousand words… but does it add utility to a nomogram to predict extraprostatic extension?

Moore CM.

BJU Int. 2018 Dec;122(6):915-916. doi: 10.1111/bju.14478. No abstract available.

35.

Prostate cancer diagnostic pathway: Is a one-stop cognitive MRI targeted biopsy service a realistic goal in everyday practice? A pilot cohort in a tertiary referral centre in the UK.

Bass EJ, Freeman A, Jameson C, Punwani S, Moore CM, Arya M, Emberton M, Ahmed HU.

BMJ Open. 2018 Oct 24;8(10):e024941. doi: 10.1136/bmjopen-2018-024941.

36.

Sequential prostate MRI reporting in men on active surveillance: initial experience of a dedicated PRECISE software program.

Giganti F, Allen C, Piper JW, Mirando D, Stabile A, Punwani S, Kirkham A, Emberton M, Moore CM.

Magn Reson Imaging. 2019 Apr;57:34-39. doi: 10.1016/j.mri.2018.10.013. Epub 2018 Oct 20.

PMID:
30352271
37.

Analysis of Drugs in Oral Fluid Using LC-MS/MS.

Coulter CA, Moore CM.

Methods Mol Biol. 2019;1872:237-259. doi: 10.1007/978-1-4939-8823-5_22.

PMID:
30350295
38.

Resting-state functional connectivity, cortical GABA, and neuroactive steroids in peripartum and peripartum depressed women: a functional magnetic resonance imaging and spectroscopy study.

Deligiannidis KM, Fales CL, Kroll-Desrosiers AR, Shaffer SA, Villamarin V, Tan Y, Hall JE, Frederick BB, Sikoglu EM, Edden RA, Rothschild AJ, Moore CM.

Neuropsychopharmacology. 2019 Feb;44(3):546-554. doi: 10.1038/s41386-018-0242-2. Epub 2018 Oct 17.

39.

Discovery of the actinoplanic acid pathway in Streptomyces rapamycinicus reveals a genetically conserved synergism with rapamycin.

Mrak P, Krastel P, Pivk Lukančič P, Tao J, Pistorius D, Moore CM.

J Biol Chem. 2018 Dec 28;293(52):19982-19995. doi: 10.1074/jbc.RA118.005314. Epub 2018 Oct 16.

40.

A Dedicated Prostate MRI Teaching Course Improves the Ability of the Urologist to Interpret Clinically Significant Prostate Cancer on Multiparametric MRI.

Kasivisvanathan V, Ambrosi A, Giganti F, Chau E, Kirkham A, Punwani S, Allen C, Emberton M, Moore CM.

Eur Urol. 2019 Jan;75(1):203-204. doi: 10.1016/j.eururo.2018.09.033. Epub 2018 Oct 14. No abstract available.

PMID:
30327275
41.

Comparing a Statistical Model and Bayesian Approach to Establish the Design Space for the Coating of Ciprofloxacin HCl Beads at Different Scales of Production.

Kothari BH, Fahmy R, Claycamp HG, Moore CMV, Chatterjee S, Hoag SW.

AAPS PharmSciTech. 2018 Nov;19(8):3809-3828. doi: 10.1208/s12249-018-1116-y. Epub 2018 Oct 2.

PMID:
30280352
42.

Prostate Imaging Compared to Transperineal Ultrasound-guided biopsy for significant prostate cancer Risk Evaluation (PICTURE): a prospective cohort validating study assessing Prostate HistoScanning.

Simmons LAM, Kanthabalan A, Arya M, Briggs T, Charman SC, Freeman A, Gelister J, Jameson C, McCartan N, Moore CM, van der Muelen J, Emberton M, Ahmed HU.

Prostate Cancer Prostatic Dis. 2019 May;22(2):261-267. doi: 10.1038/s41391-018-0094-1. Epub 2018 Oct 2.

PMID:
30279583
43.

Roadmaps and Detours: Active Chlorophyll- a Assessments of Primary Productivity Across Marine and Freshwater Systems.

Hughes DJ, Campbell DA, Doblin MA, Kromkamp JC, Lawrenz E, Moore CM, Oxborough K, Prášil O, Ralph PJ, Alvarez MF, Suggett DJ.

Environ Sci Technol. 2018 Nov 6;52(21):12039-12054. doi: 10.1021/acs.est.8b03488. Epub 2018 Oct 5.

44.

Structural and functional characterization of IdiA/FutA (Tery_3377), an iron-binding protein from the ocean diazotroph Trichodesmium erythraeum.

Polyviou D, Machelett MM, Hitchcock A, Baylay AJ, MacMillan F, Moore CM, Bibby TS, Tews I.

J Biol Chem. 2018 Nov 23;293(47):18099-18109. doi: 10.1074/jbc.RA118.001929. Epub 2018 Sep 14.

45.

Editorial Comment.

Moore CM.

J Urol. 2018 Nov;200(5):1121. doi: 10.1016/j.juro.2018.06.085. Epub 2018 Aug 17. No abstract available.

PMID:
30121169
46.

MRI in active surveillance: a critical review.

Stavrinides V, Giganti F, Emberton M, Moore CM.

Prostate Cancer Prostatic Dis. 2019 Mar;22(1):5-15. doi: 10.1038/s41391-018-0077-2. Epub 2018 Aug 16. Review.

PMID:
30115960
47.

MRI in prostate cancer diagnosis: do we need to add standard sampling? A review of the last 5 years.

Stabile A, Giganti F, Emberton M, Moore CM.

Prostate Cancer Prostatic Dis. 2018 Nov;21(4):473-487. doi: 10.1038/s41391-018-0071-8. Epub 2018 Aug 13. Review.

PMID:
30104656
48.

Handling heme: The mechanisms underlying the movement of heme within and between cells.

Donegan RK, Moore CM, Hanna DA, Reddi AR.

Free Radic Biol Med. 2019 Mar;133:88-100. doi: 10.1016/j.freeradbiomed.2018.08.005. Epub 2018 Aug 6. Review.

PMID:
30092350
49.

MRI-Targeted Biopsy for Prostate-Cancer Diagnosis.

Kasivisvanathan V, Emberton M, Moore CM.

N Engl J Med. 2018 Aug 9;379(6):589-590. doi: 10.1056/NEJMc1807507. No abstract available.

PMID:
30089067
50.

The natural history of prostate cancer on MRI: lessons from an active surveillance cohort.

Giganti F, Moore CM, Punwani S, Allen C, Emberton M, Kirkham A.

Prostate Cancer Prostatic Dis. 2018 Nov;21(4):556-563. doi: 10.1038/s41391-018-0058-5. Epub 2018 Jul 23.

PMID:
30038388

Supplemental Content

Loading ...
Support Center